Treatment of Obstructive Sleep Apnea Syndrome Related Hypertension with Aliskiren (Rasilez): a Single Center, One-Armed, Open-Label Clinical Trial.

Treatment of Obstructive Sleep Apnea Syndrome Related Hypertension with Aliskiren: a Single Center, One-Armed, Open-Label Clinical Trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028215

Enrollment

Unknown

Registered

2019-12-15

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension in Obstructive Sleep Apnea Syndrome(OSAS) patients

Interventions

Case series:Aliskiren

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary patients with informed consents; 2. Patients >= 18 years old; 3. Patients with mild hypertension(140 < msSBP < 160 mmHg, 90<msDBP <100 mmHg); 4. Polysomnography monitoring hypopnea index (apnea + hypopnea times per hour) 5-30 times per hour, and arterial oxygen saturation Spo2 SaO2 80-90%; 5. Patients without antihypertensive medication or continuous positive airway pressure (CPAP) treatment.

Exclusion criteria

Exclusion criteria: 1. Secondary hypertension; 2. Respiratory failure; 3. Heart failure(NYNA III-IV); 4. Severe renal dysfunction(eGFR= 2.5 times of the upper limit of the reference range; 6. Allergic to aliskiren; 7. History of angioedema caused by aliskiren; 8. Patients needed to receive treatment of cyclosporine A, itraconazole, quinidine, or verapamil. 9. Pregnancy or lactation; 10. Patients with maligant tumour; 11. Patients with allergic constitution.

Design outcomes

Primary

Measure	Time frame
24h ambulatory blood pressure measurement;Clinic Blood Pressure;blood pressure rhythm and variability;	—

Secondary

Measure	Time frame
sleep rhythm(total sleep time, power, ratio of phases);	—

Countries

China

Contacts

Public ContactCheng Wenli

Beijing Anzhen Hospital, Capital Medical University

chengwenli2000@163.com+86 010 64456777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026